PCF11 and pachyonychia congenita: Together with the observation that concomitant high levels of CPSF3 and PCF11 represent a negative prognostic factor for PC patients, these data strongly suggest that pharmacological inhibition of the CPA process represents a valuable therapeutic opportunity for advanced CRPC.